cox 189 has been researched along with Osteoarthritis, Knee in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J | 1 |
| Beier, J; Geusens, P; Gitton, X; Hasler, P; Moore, A; Patel, SK; Poór, G; Schnitzer, TJ; Senftleber, I; Sloan, VS | 1 |
| Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H | 1 |
| Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S | 1 |
| Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH | 1 |
6 trial(s) available for cox 189 and Osteoarthritis, Knee
| Article | Year |
|---|---|
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Placebos; Surveys and Questionnaires; Treatment Outcome | 2004 |
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2005 |
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2006 |